Pfizer Teams Up with JD Health to Fast‑Track Cutting‑Edge Medicines for a Healthier China

Pfizer’s China arm is racing toward its bold 2030 vision: to bring 60 breakthrough drugs and new uses to Chinese patients. Thanks to a supportive innovation climate, the company has already cleared more than half that target. In the past year alone, several first‑in‑class treatments have earned approval, including Sunaven® (a powerful injection for tough infections), Enoraz® (for a rare blood cancer), and Tazenna® (a capsule that tackles DNA‑repair defects in tumors). The spotlight at the recent China International Import Expo fell on Zavegepant™ – the world’s first nasal spray for acute migraine. By delivering medication straight to the nose, it sidesteps the stomach‑related side effects of pills and works faster, offering new hope for migraine sufferers across China. Pfizer also showcased progress on other products such as Briensa® (a tablet for certain lung cancers) and VazeGam® (a dissolvable tablet for migraine relief). Partnering with JD Health’s digital platform, the company aims to make these innovations more accessible, using smart technology to streamline prescribing, delivery, and patient support. Together, Pfizer and JD Health are turning high‑tech ideas into real‑world health benefits, accelerating the journey toward a healthier nation.

Read more

Big Pharma Goes All‑In on China: New R&D Hubs, Factories, and $5 Billion in Investments

At the 10th China Pharmaceutical Innovation and Investment Conference, industry leaders highlighted a dramatic shift: China is no longer just a sales market, it’s becoming a global engine of drug discovery. More than half of the new molecular entities (INDs) approved by the U.S. FDA in 2024 originated from Chinese research, a fact underscored by former FDA chief Scott Gottlieb. Multinational giants are responding fast. In October alone, eight major firms—including AstraZeneca, Eli Lilly, Pfizer, Bayer, and Medtronic—announced new R&D centers or factories in China. AstraZeneca is pouring $2.5 billion into a second strategic R&D hub in Beijing, while Boehringer Ingelheim plans over RMB 5 billion for local production of its diabetes drug Linagliptin and a five‑year R&D boost. Medtronic opened its first digital medical‑innovation base, calling China a key driver of global tech advances. The numbers back the hype: China now accounts for 38% of the world’s first‑approved innovative drugs and holds more than 20% of the top 100 life‑science institutions on the Nature Index. Clinical trial filings have surged five‑fold since 2015, and Chinese companies are regularly featured in breakthrough sessions at international conferences. Together, these moves signal a new era where multinational pharma sees China as a source of breakthrough molecules, a partner in development, and an essential link in their worldwide supply chain.

Read more